Clinical course and management of COVID-19 in the era of widespread population immunity
The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …
humans. The current high levels of population immunity, due to prior infection and/or …
Drug treatment of COVID-19 infection
G Lui, G Guaraldi - Current Opinion in Pulmonary Medicine, 2023 - journals.lww.com
Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA. 4 and BA. 5 in Colorado, USA: a retrospective …
NR Aggarwal, KC Molina, LE Beaty… - The Lancet Infectious …, 2023 - thelancet.com
Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …
[HTML][HTML] COVID-19 surveillance after expiration of the public health emergency declaration―United States, May 11, 2023
BJ Silk - MMWR. Morbidity and Mortality Weekly Report, 2023 - cdc.gov
Changes to the national COVID-19 monitoring strategy and COVID Data Tracker capitalize
on marked improvements in multiple surveillance systems. Weekly COVID-19 hospital …
on marked improvements in multiple surveillance systems. Weekly COVID-19 hospital …
Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians
A Qaseem, V Snow, JT Cross Jr… - Annals of internal …, 2008 - acpjournals.org
Description: The American College of Physicians and American Academy of Family
Physicians developed this guideline to present the available evidence on current …
Physicians developed this guideline to present the available evidence on current …
Safety and efficacy of Paxlovid against Omicron variants of coronavirus disease 2019 in elderly patients
C Weng, R Xie, G Han, Y Yuan, S Li, C Wang… - Infectious Diseases and …, 2023 - Springer
Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective
therapeutic interventions are urgently required. We clarified the safety and efficacy of …
therapeutic interventions are urgently required. We clarified the safety and efficacy of …
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents
CA Gentry, P Nguyen, SK Thind, G Kurdgelashvili… - Journal of infection, 2023 - Elsevier
Objectives Molnupiravir and nirmatrelvir/ritonavir each became available in the United
States (US) through the Food and Drug Administration (FDA) emergency use authorization …
States (US) through the Food and Drug Administration (FDA) emergency use authorization …
Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare system
JA Lewnard, JM McLaughlin, D Malden, V Hong… - medRxiv, 2022 - medrxiv.org
ABSTRACT Background In the United States, oral nirmatrelvir-ritonavir (Paxlovid™) is
authorized for use among patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 …
authorized for use among patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 …
Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated …
SE Smith-Jeffcoat, JE Biddle, HK Talbot… - Clinical Infectious …, 2024 - academic.oup.com
Abstract Background Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …
[HTML][HTML] Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a …
Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …
properties have shown promise in the treatment of COVID-19, but few trials have studied …